Advertisement
UK markets close in 1 hour 24 minutes

  • FTSE 100

    8,364.45
    -52.00 (-0.62%)
     

  • FTSE 250

    20,722.83
    -60.54 (-0.29%)
     

  • AIM

    804.78
    -2.31 (-0.29%)
     

  • GBP/EUR

    1.1755
    +0.0049 (+0.42%)
     

  • GBP/USD

    1.2741
    +0.0029 (+0.23%)
     

  • Bitcoin GBP

    54,614.78
    -858.28 (-1.55%)
     

  • CMC Crypto 200

    1,503.97
    -22.44 (-1.47%)
     

  • S&P 500

    5,321.89
    +0.48 (+0.01%)
     

  • DOW

    39,849.60
    -23.39 (-0.06%)
     

  • CRUDE OIL

    77.68
    -0.98 (-1.25%)
     

  • GOLD FUTURES

    2,415.40
    -10.50 (-0.43%)
     

  • NIKKEI 225

    38,617.10
    -329.83 (-0.85%)
     

  • HANG SENG

    19,195.60
    -25.02 (-0.13%)
     

  • DAX

    18,712.59
    -14.17 (-0.08%)
     

  • CAC 40

    8,100.25
    -41.21 (-0.51%)
     
Money:

How to protect your finances during divorce

However you do it divorce will leave you poorer, and you will need to watch your finances carefully

Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time

Business Wire
·1-min read

GERMANTOWN, Md., April 30, 2024--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2024 financial results after market close on Monday, May 13, 2024.

Management will hold a conference call to review the Company’s first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events & Publications," and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 7182212, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430201291/en/

Contacts

Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com